NEW YORK (GenomeWeb) – Having just pulled down $8.5 million in funding from a $21.5 million Series B round closed in early 2012, Miragen Therapeutics is gearing up to file investigational new drug applications for up to two of its proprietary microRNA drug candidates before the end of this year.

In doing so, the company is laying the groundwork for clinical studies that it hopes will generate proof-of-concept data around its therapeutic approach in order to woo investors for a planned initial public offering next year, Miragen President and CEO Bill Marshall told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.